🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Turkey / NCT07169227
Starting soon Phase 4

Lidocaine, Paracetamol, and Dexmedetomidine for Rocuronium Injection Pain

NCT07169227 · tracked via the Priya Life Science Turkey tracker
Phase
Phase 4
Started
2025-09
Last updated
2025-09-11

Condition(s) studied

Propofol Injection PainRocuronium Injection Pain

Investigational drug(s) / intervention(s)

Lidocaine %2 ampoule →Dexmedetomidine →paracetamol →

Lidocaine %2 ampoule: Patients who were administered 40 mg lidocaine.

Dexmedetomidine: Patients who were administered 0.25 mg/kg dexmedetomidine.

paracetamol: Patients who were administered 50 mg paracetamol.

Study summary

Propofol and rocuronium may cause pain during intravenous injection. Various pharmacological agents are used to reduce the incidence and severity of injection pain. Among the most commonly used agents for this purpose are lidocaine, various opioids, ketamine, paracetamol, and dexmedetomidine. The aim of this study was to evaluate the comparative effect of intravenous dexmedetomidine and paracetamol versus lidocaine in preventing propofol- and rocuronium-induced pain during anesthesia induction.

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
Accepted
Inclusion Criteria: Patients who will receive propofol and rocuronium 18 - 65 years No psychiatric disorders Elective surgery Those who accept the research No history of allergy to any of the drugs used in the study Patients in American Society of Anesthesiologists (ASA) I and II class Exclusion Criteria: Patients with chronic pain syndromes Patients with difficult intravenous access Patients with advanced heart block or heart failure Patients with uncontrolled hypertension (Systolic blood pressure \>160 mmHg)

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Baskent University Adana Adana

More Baskent University trials in Turkey

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07169227 on ClinicalTrials.gov ↗ ← All trials in Turkey